ECM1 and prostate carcinoma: Mechanistically, ECM1 interacts with the ENO1 receptor on the prostate cancer cell membrane, leading to its phosphorylation, contributing to the activation of the MAPK signaling pathway, resulting in the development of tumor resistance.